This is a summary of a publication about the ARASENS trial, which was published in the New England Journal of Medicine in February 2022. The ARASENS trial looked at how well darolutamide worked when combined with androgen deprivation therapy (ADT) and docetaxel compared placebo plus ADT and docetaxel in men with metastatic, hormone-sensitive prostate cancer. The summary also includes perspectives on the ARASENS trial and prostate cancer from 3 members of the patient community.
Read the full article here.
Click here to read the original article on which this summary is based.